Navigation Links
Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
Date:8/4/2008

ine results with boceprevir are very exciting, especially given that genotype 1 is the most common and hardest to treat form of hepatitis C," said Paul Kwo, M.D., associate professor of medicine and medical director, liver transplantation, Department of Medicine, Division of Gastroenterology/Hepatology, Indiana University School of Medicine, Indianapolis, and lead investigator of the study. "Boceprevir was well tolerated by patients in this study, including those who received 48 weeks of boceprevir in the longer duration treatment arms."

Safety data from the study showed that the most common adverse events reported in the boceprevir arms were fatigue, anemia, nausea and headache. No increase in skin adverse events (rash or pruritus) beyond what was seen in the PEGINTRON and REBETOL control arm was observed. Treatment discontinuations due to adverse events were between 9 and 19 percent for patients in the boceprevir arms, compared to 8 percent for the control arm.

In the study, known as HCV SPRINT-1 (HCV Serine Protease Inhibitor Therapy-1), boceprevir (800 mg TID) was evaluated in three treatment regimens: 4 weeks of PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily based on patient weight) therapy followed by the addition of boceprevir to the combination for 24 or 44 weeks (totaling 28 or 48 weeks of treatment); boceprevir in combination with PEGINTRON and REBETOL at the doses described above for 28 or 48 weeks; and boceprevir in combination with PEGINTRON and low-dose REBETOL (400-1000 mg daily) for 48 weeks, compared to a control of PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily based on patient weight) alone for 48 weeks (an approved treatment regimen). The primary endpoint of the study is SVR after 24 weeks of follow up (SVR 24). This is an ongoing study and SVR 24 rates are not yet available for patients in the 48-week boceprevir arms or the 48-week control arm of the study.

Sustai
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
2. NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
3. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
4. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
5. Inspires Phase 3 CF Trial, Using PARIs Nebulizer & Compressor, Shows Positive Top-Line Results
6. Cardica Reports Positive Top-Line Results and Submits 510(k) for PAS-Port(R) Proximal Anastomosis System in Cardiac Bypass Surgery
7. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
8. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
9. Schering-Plough Reports Top-Line Results of the IDEAL Study
10. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
11. Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , Net Sales of $1.17 billion represent a decrease ... increase of 5.7% constant currency , Reported net loss ... earnings per share were $1.59, an increase of 0.6% over ... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ... 2015.  The Company reported second quarter net sales of $1.17 ...
(Date:7/29/2015)... July 30, 2015  Astellas today announced topline ... the efficacy and safety of intravenous (IV) and ... under development for adults with candidemia and other ... study demonstrated that the trial did not meet ... response in isavuconazole-treated patients at the end of ...
(Date:7/29/2015)... SAN FRANCISCO , July 29, 2015  Nektar Therapeutics ... the second quarter ended June 30, 2015 on Wednesday, August ... Howard Robin , president and chief executive officer, will host ... p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... the conference call can be accessed through a link that ...
Breaking Medicine Technology:Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 2Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 3Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 4Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 5Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 6Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 7Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 8Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 9Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 10Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 11Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 12Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 13Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 14Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 15Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 16Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 17Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 18Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 19Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 20Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 21Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 22Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 23Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 24Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 25Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 26Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 27Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 28Zimmer Biomet Holdings, Inc. Reports Second Quarter 2015 Financial Results 29Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets 2Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets 3
... YORK, May 19, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0503653/Pharmaceutical-Management-of-Obesity-Technical-Insights.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication ... a lot of research and product development ...
... 2011 Genomic Health, Inc. (Nasdaq: GHDX ... from ten separate studies at the American Society of ... 2011 at McCormick Place in Chicago.  The company markets ... which is clinically validated to predict chemotherapy benefit as ...
Cached Medicine Technology:Reportlinker Adds Pharmaceutical Management of Obesity (Technical Insights) 2Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 3Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 4Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 5Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 6Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 7
(Date:7/30/2015)... ... , ... New research finds some distinct differences in the way mesothelioma behaves ... Surviving Mesothelioma website. , Researchers with the National Institutes of Health, the FDA, ... mesothelioma occurring between 1990 and 2010. Two percent of these cases (207) occurred in ...
(Date:7/30/2015)... ... July 30, 2015 , ... Political unrest is ... according to a new survey by leading international insurance provider Clements Worldwide. The ... medical expenses represented the largest sources of financial losses among respondents. , Twenty-eight ...
(Date:7/30/2015)... ... July 30, 2015 , ... HEALTHCAREfirst , the leading provider of ... that it is hosting a free webinar detailing the 2016 proposed rule from CMS ... and former Vice President of Regulatory Affairs for the National Association for Home Care ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... manufacturing and packaging services for consumer brands, recently completed a consolidation of all ... MD. Previously, the company operated out of two separate locations situated 11 miles ...
(Date:7/29/2015)... ... 2015 , ... Macro Wealth Management (MWM) Presidents have increased the ... program by encouraging their clients to donate their MWM planning fees to the Foundation. ... and Tim Streid, who see charitable giving as an important part of financial planning ...
Breaking Medicine News(10 mins):Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3Health News:HEALTHCAREfirst Announces Home Health Industry Regulatory Review Webinar 2Health News:Case Mason Consolidates Operations to Larger Facility for Increased Efficiency, Improved Service 2Health News:Case Mason Consolidates Operations to Larger Facility for Increased Efficiency, Improved Service 3Health News:Smile for a Lifetime (S4L) Partners with Macro Wealth Management (MWM) Helping More Children Get Braces 2
... Entire Health Care System More EffectiveWASHINGTON, Jan. 5 ... avoid hospitalization by using special technology provided by the ... to a recent study. "The study showed that ... improves patients, access to care and is easy to ...
... Inc. (Nasdaq: MSON ), a developer of ... is used for the ablation of tumors and worldwide ... definitive, 3-year distribution agreement with Alliance Lithomobile, a Division ... This agreement supersedes the interim agreement announced on November ...
... Only 17 percent of Spanish-speaking women of childbearing age ... folic acid daily, according to the first- nationally representative ... , Folic acid can prevent neural tube defects ... such as spina bifida and anencephaly, which are more ...
... Jan. 5 Cambrex Corporation (NYSE: ... M. Klosk, President and Chief Executive Officer, will ... January 13, 2009 at 9:00 a.m. PST at ... (Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO )A live ...
... new study reveals that the metadherin gene (MTDH) plays ... chemotherapy. The research, published by Cell Press in the ... , identifies MTDH as a promising therapeutic target for ... resist currently available therapeutic regimens and succumb to recurrent ...
... to help healthcare providers put a cap on ... Corporation ( MSC ) will introduce a new ... all healthcare team members who care for hospital ... on medical simulation , the International Meeting ...
Cached Medicine News:Health News:VA Data Show Home Health Technology Improves Access to Care 2Health News:Misonix Announces New HIFU Distribution Agreement for Italy 2Health News:Misonix Announces New HIFU Distribution Agreement for Italy 3Health News:Folic acid survey of Spanish-speaking women finds most are missing benefits, March of Dimes says 2Health News:Gene plays dual role in breast cancers with poor prognosis 2Health News:Medical Simulation Corporation to Introduce Ventilator Associated Pneumonia Program at International Meeting on Simulation in Healthcare 2Health News:Medical Simulation Corporation to Introduce Ventilator Associated Pneumonia Program at International Meeting on Simulation in Healthcare 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: